This is a summary of the European public assessment report (EPAR) for Bondronat. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bondronat.
Therapeutic Indication
### Therapeutic indication Bondronat is indicated for: - prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases; - treatment of tumour-induced hypercalcaemia with or without metastases.
Therapeutic Area (MeSH)
ATC Code
M05BA06
ATC Item
ibandronic acid
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ibandronic acid | N/A | 伊班膦酸钠 |
EMA Name
Bondronat
Medicine Name
Bondronat
Aliases
N/ANo risk management plan link.
